Anticoagulants: A Global Strategic Business Report
San Jose, California (Vocus) September 28, 2010
Anticoagulants are a rapidly evolving market for available and emerging treatment regimes. Dominated by just two therapy classes – vitamin K antagonist and heparin injectables, enormous opportunities exist for the development of advanced and patient/physician friendly anticoagulants. The anticoagulants industry has come a long way since 1990s, when advancements in thrombotic disease detection, increased physician awareness, and vigorous treatment were major drivers for market growth. Market growth is led by the arrival of novel therapeutics, complex treatment procedures, patent expiries, competition, as well as demographic settings.
The United States and Europe dominate the global anticoagulants market, as stated by the new market research report on Anticoagulants. Anticoagulants market is likely to grow dramatically as advanced therapeutics present brighter prospects for coagulation as well as patient management. While novel drugs are likely to impact the market sometime in near future, factors that already influence market prospects include increasing use of low molecular weight heparins, patient population, and additional indications for existing drugs. Future impact of novel anticoagulants is expected to mainly result from enormous patient potential, despite presence of major overlaps. Among these, aging population at growing risk of venous and arterial problems and patients on long-term anticoagulation would be the major influencers.
Oral anticoagulants is among the most promising segments for thrombosis, and is likely to benefit immensely from the fact that the present best sellers are injectable versions. The approval of several new agents is also likely to drive growth in the market, by offering better standards of care for the users. The availability of oral anticoagulants is expected to prove beneficial for the stroke prevent caused by atrial fibrillation, which in turn is expected to lead to a decline in the use of warfarin for the indication. The rapid adoption of new oral anticoagulants and the launch of novel products is expected to drive growth in the global venous thromboembolism drug market, particularly in the US, Japan, France, Germany, UK, and Italy.
Some of the novel oral anticoagulants set for launch include Boehringer Ingelheim's Pradaxa (dabigatran etexilate), Xarelto (rivaroxaban) from Bayer/Johnson & Johnson, and apixaban from Bristol-Myers Squibb/Pfizer. From 2010, the predominance of low molecular weight heparins is expected to reduce gradually through the next decade, owing to the launch and rising penetration of several new oral agents.
The global anticoagulants market is controlled by warfarin (vitamin K antagonist), unfractionated heparin and low molecular weight heparins (heparins). Injectable anticoagulants market has maintained a steady pace over the years with more number of patients receiving anticoagulation with one or more of the injectable therapies. The market comprises of the long established unfractionated heparin (UFH), recently recognized low molecular weight heparins (LMWH), and the emerging non-heparin injectables.
Major players profiled in the report include AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, LEO Pharmaceutical Products, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Sanofi-Aventis, and Teva Pharmaceutical Industries Ltd.
The report titled “Anticoagulants: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a review of market trends, product introductions/innovations, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including the United States, Japan, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Anticoagulants_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/